Results 111 to 120 of about 2,475,393 (270)

Association of GLP‐1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Dazheng Zhang   +7 more
wiley   +1 more source

Linagliptin increases the expression of LRP2 independent of Nrf2 in streptozotocin‐induced diabetic mice

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Oxidative stress is thought to play a role in the onset and progression of diabetic nephropathy (DN). Nuclear factor erythroid‐related factor 2 (Nrf2) is a master regulator of antioxidant and detoxification pathways and provides cellular protection against oxidative stress.
Suratsawadee Promsuwan   +5 more
wiley   +1 more source

Toward “Obesityomics”: Domain‐Specific Omics in Precision Obesity Medicine with a Brief AI Perspective

open access: yesObesity Reviews, EarlyView.
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra   +13 more
wiley   +1 more source

Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study

open access: yesOral Diseases, EarlyView.
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai   +5 more
wiley   +1 more source

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review

open access: yesFrontiers in Pharmacology
In the realm of clinical management, Papillary Thyroid Cancer (PTC) stands out as a prevalent thyroid malignancy, characterized by significant metabolic challenges, particularly in the context of carbohydrate metabolism.
Angelika Buczyńska   +4 more
doaj   +1 more source

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

open access: yesTherapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin   +6 more
doaj   +1 more source

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes

open access: yes, 2008
Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian LerchCochrane Metabolic and Endocrine Disorders Group, Department of General Practice, Heinrich-Heine University Duesseldorf, Duesseldorf, GermanyBackground: In type 2 diabetes ...
Elizabeth Bandeira-Echtler   +3 more
core  

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema

open access: yes
Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals.
Harris, S   +10 more
core   +1 more source

Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors

open access: yes, 2009
[[abstract]]A series of (2S)-cyanopyrrolidines with glutamic acid derivatives at the P2 site have been prepared and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV).
Tsai, TY;Hsu, T;Chen, CT;Cheng, JH;Chiou, MC;Huang, CH;Tseng, YJ;Yeh, TK;Huang, CY;Yeh, KC;Huang, YW;Wu, SH;Wang, MH;Chen, X;Chao, YS;Jiaang, WT
core   +1 more source

Home - About - Disclaimer - Privacy